Outpatiented · Case Knowledge
A 41-year-old woman with ptosis, diplopia, dysphagia, and progressive worsening over four months. She has a history of two thyroidectomies. She is on Adderall, Abilify, and clonazepam. The system might chase medication side effects or psychiatric explanations. The right move is to rule out myasthenia gravis first.
What Myasthenia Gravis Is
Myasthenia gravis is an autoimmune disease in which the body produces antibodies that attack the neuromuscular junction, the synapse where nerve signals tell muscles to contract. The most common target is the acetylcholine receptor (AChR). When these receptors are blocked or destroyed, the muscle cannot respond normally to nerve signals.
The defining feature is fatigability: weakness that worsens with sustained or repeated use of a muscle, and improves with rest. This is not ordinary tiredness. It is a specific pattern, muscles work initially, then progressively fail as acetylcholine is depleted faster than the damaged junction can respond.
The muscles most commonly affected first are those controlling eye movements and eyelid elevation (ocular muscles), followed by swallowing, speech, and facial expression. Generalized MG progresses to involve limb and respiratory muscles. The pattern, eyes first, then bulbar symptoms, is characteristic and diagnostically important.
MG is predominantly an antibody-mediated disease, which connects it directly to other autoimmune conditions. A patient with one antibody-mediated autoimmune disease has a substantially elevated risk of developing others. Autoimmune thyroid disease and MG share this mechanism and co-occur at rates far above chance.
Weakness that worsens with use and improves with rest
is not fatigue. It is fatigability. The distinction is the diagnosis.
Why This Presentation Is High Suspicion
When multiple independent features each raise the probability of a diagnosis, their combined weight becomes compelling. This presentation has several.
Ptosis, drooping of the eyelid due to weakness of the levator palpebrae muscle, is one of the most characteristic early signs of MG. It is often asymmetric, can shift from eye to eye, and classically worsens with sustained upward gaze. The ice pack test, a simple bedside exam, exploits the fact that cooling improves neuromuscular transmission: placing an ice pack on a ptotic eyelid for two minutes that then improves is a positive test. Sensitivity is approximately 80% for ocular MG.
Diplopia in MG results from uneven weakness of the muscles that coordinate eye movement. Unlike structural causes of diplopia (nerve palsy, orbital disease), MG-related diplopia characteristically varies, worse with fatigue, better after rest. The pattern of diplopia may shift depending on which muscles are most affected at a given moment. Visual disturbances that fluctuate with fatigue and improve with rest strongly favor a neuromuscular junction disorder.
Difficulty swallowing in MG reflects weakness of the pharyngeal and palatal muscles. The patient's description, thinking about swallowing before doing it, captures the conscious compensation that occurs when automatic neuromuscular function is impaired. Dysphagia in MG is a bulbar symptom, and bulbar involvement raises the risk of aspiration and myasthenic crisis. This is what makes the presentation urgent rather than routine. Swallowing difficulty in a patient with MG needs to be evaluated and monitored, not deferred.
MG does not typically fluctuate randomly. It progresses if untreated. Four months of worsening ptosis, diplopia, and dysphagia is a disease progressing through its natural course. This is not an acute episode with a clear precipitant. It is a trajectory that argues for a structural underlying diagnosis rather than a medication effect or situational cause.
MG has a bimodal age distribution: women predominantly in their 20s-40s (often antibody-positive, thymus-associated) and men predominantly in their 60s-70s. A woman in her early 40s with new ptosis, diplopia, and dysphagia sits squarely in the highest-probability demographic for MG in women. Age and sex are prior probability. They do not establish the diagnosis, but they raise it.
Autoimmune thyroid disease (Graves' disease, Hashimoto's thyroiditis) and myasthenia gravis are both antibody-mediated autoimmune conditions with overlapping immune dysregulation pathways. They co-occur at substantially elevated rates. A patient who has required two thyroid surgeries has a significant autoimmune history. This history does not cause MG, but it tells you that this patient's immune system has already demonstrated the capacity to generate pathological autoantibodies against self-tissue. The pretest probability of MG in this patient is materially higher than in the general population.
Medications in Context
Three medications are on board: Adderall 60mg, Abilify (tapering), and clonazepam. Each deserves consideration, not because they are the likely explanation, but because they affect how the clinical picture reads.
The Workup
MG workup is specific and highly confirmatory when the clinical picture is strong. A negative AChR antibody does not rule out MG, seronegative MG is real. The full workup rules it in or out definitively.
Acetylcholine receptor antibodies are the most specific diagnostic test for MG. Positive in approximately 85% of generalized MG cases and 50-60% of purely ocular MG. A positive result confirms the diagnosis. A negative result does not rule it out, 15% of generalized MG patients are AChR-seronegative.
Muscle-specific kinase (MuSK) antibodies are found in approximately 40% of AChR-negative MG patients. MuSK-MG tends to have prominent bulbar and facial involvement, which fits this presentation. Testing for MuSK antibodies when AChR is negative is standard protocol and catches a significant proportion of seronegative cases.
Cooling slows the degradation of acetylcholine at the neuromuscular junction and temporarily improves transmission. Applying an ice pack through a cloth to the ptotic eyelid for two minutes and measuring whether ptosis improves is a simple, specific, and immediate bedside test. Approximately 80% sensitivity for ocular MG. Can be done in a clinic before any blood or EMG results return.
Single-fiber electromyography measures the variability in timing between two muscle fibers from the same motor unit, a phenomenon called jitter. Increased jitter indicates impaired neuromuscular transmission. Sensitivity exceeds 95% for generalized MG and approximately 85-90% for purely ocular MG. It is the most sensitive test available and is the study to pursue when clinical suspicion is high but antibodies are negative.
Repetitive nerve stimulation at low frequency in MG produces a characteristic decremental response, the electrical signal of successive muscle contractions gets progressively smaller. Less sensitive than single-fiber EMG (approximately 75% for generalized MG) but widely available and often performed first as part of a standard EMG study.
The thymus gland plays a central role in MG pathophysiology. Approximately 10-15% of MG patients have a thymoma (thymus tumor), and 50-60% have thymic hyperplasia. Thymoma-associated MG is a distinct clinical entity requiring surgical evaluation. CT of the chest to evaluate the thymus is standard in the initial MG workup. Given this patient's prior autoimmune history. This is not optional.
Myasthenic crisis is a life-threatening exacerbation of MG in which respiratory muscle weakness is severe enough to require mechanical ventilation. It is the most dangerous complication of the disease and can develop rapidly from a bulbar presentation.
Dysphagia in MG indicates that bulbar musculature, the muscles of swallowing and airway protection, is involved. Patients with bulbar involvement are at higher risk of aspiration, respiratory compromise, and crisis. The step from dysphagia to respiratory failure can be faster than expected.
This does not mean crisis is imminent. It means this patient should be evaluated urgently by a neurologist with experience in MG, not seen in several weeks. If dysphagia worsens, nasal voice develops, or any sense of breathing difficulty appears, that is an emergency department presentation.
Questions People Actually Ask
What does myasthenia gravis feel like early on?
The earliest symptoms of MG most commonly involve the eyes: drooping of one or both eyelids (ptosis) and double vision (diplopia). These may initially appear intermittently, worse in the evening or after sustained eye use, better in the morning or after rest. Many patients describe their eyelid drooping appearing later in the day or after reading or screen time.
The key distinguishing feature is fatigability: symptoms are worse with sustained activity and improve with rest. This is different from ordinary fatigue. Someone with MG-related ptosis may be able to hold their eyes open normally at the start of the day but find them drooping progressively through it. That pattern, worsening with use, recovering with rest, is characteristic of neuromuscular junction disease rather than structural or neurological causes.
What is the connection between thyroid disease and myasthenia gravis?
Both Graves' disease (autoimmune hyperthyroidism) and Hashimoto's thyroiditis (autoimmune hypothyroidism) are antibody-mediated autoimmune conditions, as is myasthenia gravis. Patients with one antibody-mediated autoimmune disease have a significantly elevated risk of developing others, a phenomenon called polyautoimmunity.
Studies show that MG patients have a higher-than-expected prevalence of autoimmune thyroid disease, and vice versa. The immune dysregulation that leads the body to produce antibodies against thyroid tissue also predisposes it to produce antibodies against neuromuscular junction components. A history of thyroidectomy, particularly for Graves' disease, raises the pretest probability of MG meaningfully in a patient presenting with compatible symptoms.
What is a myasthenic crisis and how do I know if it is happening?
Myasthenic crisis is a severe exacerbation of MG in which respiratory muscle weakness becomes severe enough to cause respiratory failure, requiring mechanical ventilation. It is a medical emergency.
Warning signs that crisis may be developing: shortness of breath, especially when lying flat; inability to take a deep breath; nasal or hypernasal voice; worsening difficulty swallowing with pooling of secretions; rapid deterioration in previously stable symptoms. Any of these in a known or suspected MG patient is an emergency department presentation, not a call to the neurologist's office the next morning.
Crisis can be triggered by infection, surgery, certain medications, or can occur without clear cause. Patients with bulbar involvement (swallowing difficulty, nasal voice) are at higher baseline risk than those with only ocular symptoms.
Can Adderall or other medications cause symptoms that look like myasthenia gravis?
Adderall at high doses can occasionally cause visual disturbances through its sympathomimetic effects, but it does not cause ptosis or dysphagia, the two symptoms most specific to MG in this presentation. Clonazepam can cause sedation and some generalized weakness but does not produce the characteristic fatigable ocular and bulbar picture.
The more relevant concern runs in the opposite direction: Adderall at 60mg may mask the fatigability pattern by providing stimulant-driven energy that obscures the characteristic worsening with sustained activity. If symptoms seem temporarily better at the peak of Adderall's effect and return as it wears off. That is not reassuring. It is consistent with the underlying fatigability being pharmacologically suppressed.
If MG is confirmed, certain medications become relevant as potential triggers for worsening: fluoroquinolone and aminoglycoside antibiotics, beta blockers, magnesium sulfate infusions, and neuromuscular blocking agents used in surgery. Awareness of this list matters once the diagnosis is established.
What does treatment for myasthenia gravis look like?
MG is a treatable disease. Effective therapies exist across several categories.
Pyridostigmine (Mestinon) is the first-line symptomatic treatment. It inhibits the breakdown of acetylcholine at the neuromuscular junction, increasing the availability of the neurotransmitter. It improves symptoms without affecting the underlying immune process.
Immunosuppression targets the antibody-producing immune response. Corticosteroids (prednisone) are commonly used first. Steroid-sparing agents including azathioprine, mycophenolate, and cyclosporine are used for long-term management. Rituximab is used in refractory cases, particularly MuSK-antibody MG.
Thymectomy, surgical removal of the thymus, improves outcomes in AChR-positive generalized MG, even without thymoma, and is recommended for appropriate candidates under 65.
Newer targeted therapies approved in recent years include eculizumab (complement inhibitor), efgartigimod (FcRn inhibitor that reduces antibody levels), and rozanolixizumab. These represent significant advances for refractory or severe MG.
The MAP Tool maps your symptom pattern, history, and timeline to root cause. Not a diagnosis. A thread to follow.
Start Your Map